Cargando…

Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis

Cardiovascular diseases (CVDs) have been classified into several types of disease, of which atherosclerosis is the most prevalent. Atherosclerosis is characterized as an inflammatory chronic disease which is caused by the formation of lesions in the arterial wall. Subsequently, lesion progression an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahjoubin-Tehran, Maryam, Teng, Yong, Jalili, Amin, Aghaee-Bakhtiari, Seyed Hamid, Markin, Alexander M., Sahebkar, Amirhossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122884/
https://www.ncbi.nlm.nih.gov/pubmed/33922585
http://dx.doi.org/10.3390/ijms22094420
_version_ 1783692744019935232
author Mahjoubin-Tehran, Maryam
Teng, Yong
Jalili, Amin
Aghaee-Bakhtiari, Seyed Hamid
Markin, Alexander M.
Sahebkar, Amirhossein
author_facet Mahjoubin-Tehran, Maryam
Teng, Yong
Jalili, Amin
Aghaee-Bakhtiari, Seyed Hamid
Markin, Alexander M.
Sahebkar, Amirhossein
author_sort Mahjoubin-Tehran, Maryam
collection PubMed
description Cardiovascular diseases (CVDs) have been classified into several types of disease, of which atherosclerosis is the most prevalent. Atherosclerosis is characterized as an inflammatory chronic disease which is caused by the formation of lesions in the arterial wall. Subsequently, lesion progression and disruption ultimately lead to heart disease and stroke. The development of atherosclerosis is the underlying cause of approximately 50% of all deaths in westernized societies. Countless studies have aimed to improve therapeutic approaches for atherosclerosis treatment; however, it remains high on the global list of challenges toward healthy and long lives. Some patients with familial hypercholesterolemia could not get intended LDL-C goals even with high doses of traditional therapies such as statins, with many of them being unable to tolerate statins because of the harsh side effects. Furthermore, even in patients achieving target LDL-C levels, the residual risk of traditional therapies is still significant thus highlighting the necessity of ongoing research for more effective therapeutic approaches with minimal side effects. Decoy-based drug candidates represent an opportunity to inhibit regulatory pathways that promote atherosclerosis. In this review, the potential roles of decoys in the treatment of atherosclerosis were described based on the in vitro and in vivo findings.
format Online
Article
Text
id pubmed-8122884
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81228842021-05-16 Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis Mahjoubin-Tehran, Maryam Teng, Yong Jalili, Amin Aghaee-Bakhtiari, Seyed Hamid Markin, Alexander M. Sahebkar, Amirhossein Int J Mol Sci Review Cardiovascular diseases (CVDs) have been classified into several types of disease, of which atherosclerosis is the most prevalent. Atherosclerosis is characterized as an inflammatory chronic disease which is caused by the formation of lesions in the arterial wall. Subsequently, lesion progression and disruption ultimately lead to heart disease and stroke. The development of atherosclerosis is the underlying cause of approximately 50% of all deaths in westernized societies. Countless studies have aimed to improve therapeutic approaches for atherosclerosis treatment; however, it remains high on the global list of challenges toward healthy and long lives. Some patients with familial hypercholesterolemia could not get intended LDL-C goals even with high doses of traditional therapies such as statins, with many of them being unable to tolerate statins because of the harsh side effects. Furthermore, even in patients achieving target LDL-C levels, the residual risk of traditional therapies is still significant thus highlighting the necessity of ongoing research for more effective therapeutic approaches with minimal side effects. Decoy-based drug candidates represent an opportunity to inhibit regulatory pathways that promote atherosclerosis. In this review, the potential roles of decoys in the treatment of atherosclerosis were described based on the in vitro and in vivo findings. MDPI 2021-04-23 /pmc/articles/PMC8122884/ /pubmed/33922585 http://dx.doi.org/10.3390/ijms22094420 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mahjoubin-Tehran, Maryam
Teng, Yong
Jalili, Amin
Aghaee-Bakhtiari, Seyed Hamid
Markin, Alexander M.
Sahebkar, Amirhossein
Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis
title Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis
title_full Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis
title_fullStr Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis
title_full_unstemmed Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis
title_short Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis
title_sort decoy technology as a promising therapeutic tool for atherosclerosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122884/
https://www.ncbi.nlm.nih.gov/pubmed/33922585
http://dx.doi.org/10.3390/ijms22094420
work_keys_str_mv AT mahjoubintehranmaryam decoytechnologyasapromisingtherapeutictoolforatherosclerosis
AT tengyong decoytechnologyasapromisingtherapeutictoolforatherosclerosis
AT jaliliamin decoytechnologyasapromisingtherapeutictoolforatherosclerosis
AT aghaeebakhtiariseyedhamid decoytechnologyasapromisingtherapeutictoolforatherosclerosis
AT markinalexanderm decoytechnologyasapromisingtherapeutictoolforatherosclerosis
AT sahebkaramirhossein decoytechnologyasapromisingtherapeutictoolforatherosclerosis